Skip to main content
. 2021 Jul 1;11:691318. doi: 10.3389/fonc.2021.691318

Figure 2.

Figure 2

Prognostic performance of the 12-TF signature in HNSCC. (A–C) Kaplan-Meier and ROC analysis of patients with HNSCC in entire TCGA set, the internal validation and external validation, respectively. (D–F) Kaplan-Meier analysis with two-sided log-rank test was conducted to evaluate the differences in RFS between the low-risk and high-risk cases. 1-, 3-, 5-year ROC curves of the 12-TF signature were applied to measure the value in predicting HNSCC patients’ RFS in entire TCGA set, the internal validation and external validation, respectively. (G–I) TF risk score analysis of 499 HNSCC samples in TCGA database. TF risk score distribution against the rank of risk score (G). Average risk score was set as the cut-off point. Recurrence free survival status of HNSCC patients (H). Heatmap of 12 TFs expression profiles of HNSCC patients (I). (J–L) TF risk score analysis of 270 HNSCC samples in the GEO dataset. TF risk score distribution against the rank of risk score (J). Average risk score was set as the cut-off point. Recurrence free survival status of HNSCC patients (K). Heatmap of 12 TFs expression profiles of HNSCC patients (L).